Bristol Signs Two Cancer Immunotherapy Partners With Eye On Combos
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol will pay $50 million upfront to use CytomX’s Probody platform for up to four cancer immunotherapy targets. The company also partnered with InCyte to study its PD-1 inhibitor nivolumab with Incyte’s oral indoleamine dioxygenase-1 inhibitor.
You may also be interested in...
Third Rock Leads $30 Mil. Series B For CytomX
The startup, which develops antibodies designed to act selectively on diseased tissue, has two preclinical oncology programs.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.